Fresh analysis reveals that individuals who come off popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who end conventional diet and exercise plans.
Published data in a major health publication points out that while obese individuals often shed about a fifth of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Users using these drugs should be informed of the risk of fast weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment mass within about 18 months.
Weighing Treatments
The analysis, which reviewed dozens of studies involving over 9,000 of patients, contrasted the results of the injectable medications with other pills.
The team point out that individuals who lose weight through dieting generally see a more gradual weight regain—approximately 100 grams monthly—once they finish.
Understanding the Fast Rebound
Doctors suggest the mechanism of the drugs is key to understanding the accelerated regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal could lead to the body to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to hunger is uncontrolled, making excessive eating much more probable."
A Lifelong Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts argue that, due to the high risk of relapse, the therapy might need to be long-term.
This perspective is echoed by drug manufacturers, who say that the findings "underscore the persistent nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
Users who have stopped the medication explain a intense resurgence of hunger.
"I experienced something activating and you're instantly ravenous," said a patient.
The struggle is compounded if patients have not adopted sustainable lifestyle or habit modifications during treatment.
Significant Adoption
Survey data suggest that millions of adults in the UK have used these injections in the past year, with interest remaining high.
- Use is greater among females compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are potent agents for shedding pounds, they are not a magic fix and long-term success likely depends on combined behavioural management.
